Key facts
- This page summarizes Robert Barrow's Form 4 filing for Mind Medicine (MindMed) Inc. (MNMD).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 25 Jun 2024, 19:00.
Robert Barrow - 25 Jun 2024 Form 4 Insider Report for Mind Medicine (MindMed) Inc. (MNMD)
- Reporting relationship
- Chief Executive Officer, Director
- Issuer ticker
- MNMD
- Reported as of
- 25 Jun 2024
- Net transaction value
- -$113,058
- SEC form
- 4
- Accepted by SEC
- 25 Jun 2024, 19:00:03 UTC
- Prior SEC filing
- 26 Mar 2024
- Next SEC filing
- 20 Aug 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Mark Sullivan, Attorney-in-Fact for Robert Barrow
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Robert Barrow filed Form 4 for Mind Medicine (MindMed) Inc. (MNMD) on 25 Jun 2024.
Change
- Previous filing in this sequence was filed on 26 Mar 2024.
- Current net transaction value: -$113,058.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
MNMD
transaction
Common Shares
Sale
- Transaction value
- $113,058
- Shares
- -15,659
- Change %
- -2.7%
- Price
- $7.22
- Shares after
- 564,543
- Date
- 25 Jun 2024
- Ownership
- Direct
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 2 footnotes
Footnote F1
Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on June 15, 2022.
Footnote F2
The reported price is a weighted average sales price. These shares were sold in multiple transactions on June 25, 2024 at prices ranging from $7.20 to $7.26. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.